Tyme Technologies (TYME) Upgraded to “Hold” by BidaskClub

BidaskClub upgraded shares of Tyme Technologies (NASDAQ:TYME) from a sell rating to a hold rating in a report released on Thursday morning.

Other analysts have also issued research reports about the company. Canaccord Genuity assumed coverage on Tyme Technologies in a research note on Wednesday. They set a buy rating on the stock. Evercore ISI assumed coverage on Tyme Technologies in a research note on Friday, November 17th. They set an outperform rating and a $7.00 price objective on the stock. Finally, HC Wainwright assumed coverage on Tyme Technologies in a research note on Friday, December 15th. They set a buy rating and a $8.00 price objective on the stock.

Tyme Technologies (NASDAQ:TYME) traded up $0.02 on Thursday, hitting $6.93. The company had a trading volume of 61,159 shares, compared to its average volume of 184,941. The firm has a market capitalization of $618.99, a price-to-earnings ratio of -40.76 and a beta of -0.01. Tyme Technologies has a fifty-two week low of $2.01 and a fifty-two week high of $9.50.

In other Tyme Technologies news, COO Michael Demurjian sold 50,000 shares of the firm’s stock in a transaction dated Tuesday, November 14th. The stock was sold at an average price of $3.34, for a total value of $167,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

COPYRIGHT VIOLATION WARNING: “Tyme Technologies (TYME) Upgraded to “Hold” by BidaskClub” was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.com-unik.info/2018/01/07/tyme-technologies-tyme-upgraded-to-hold-by-bidaskclub.html.

Tyme Technologies Company Profile

Tyme Technologies, Inc is a clinical-stage biotechnology company. The Company is focused on developing cancer therapeutics that is intended to be broadly effective across tumor types and have low toxicity profiles. The Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system.

What are top analysts saying about Tyme Technologies? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Tyme Technologies and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit